Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H ( (GZPHF) ) has released its Q1 earnings. Here is a breakdown of the information Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H presented to its investors.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a joint stock company based in China, operating in the pharmaceutical industry, known for its diverse range of pharmaceutical products and healthcare services. In its first quarterly report for 2025, the company reported a slight decrease in operating income and net profit compared to the same period in 2024. The company’s operating income was RMB 22.47 billion, a 2.06% decrease from the previous year, while net profit attributable to shareholders was RMB 1.82 billion, reflecting a 6.99% decline. Despite these decreases, the company saw a 5.05% increase in total equity attributable to shareholders, indicating a strong equity position. The report also highlighted a significant decrease in net cash flow from operating activities, which fell by 24.19% to negative RMB 3.9 billion. Looking ahead, the management remains focused on strategic initiatives to enhance operational efficiency and drive growth, although challenges in the operating environment persist.